Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Betahistine 48 mg TID for motion sickness
2008-000885-21Phase 4Active
- Sponsor
- TNO
- Start
- Feb 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of betahistine in motion sickness, sponsored by TNO. Primary endpoint: Exposure duration to motion stimulus. Started Feb 2008; status: active.
02
Drugs
betahistine
03
Conditions
motion sickness
Beyond the preview
Go deeper on 2008-000885-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000885-21.